An interview recorded at SupplySide Global by Nutritional Outlook has Filipa Quintela, associate director of global marketing at Kemin, setting out the three ingredient platforms the supplier expects to shape its product development. Her picks are positive aging, GLP-1 support, and gut health.
The named ingredients matter more than the trend labels. Slendesta is Kemin's satiety ingredient, and Gutopia is the gut platform holding BetaVia, described as a beta-glucan postbiotic from algae, and ButiShield, a short-chain fatty acid.
Lutein beyond the eye
Quintela says FloraGLO Lutein is backed by more than 100 clinical research publications, which is a genuinely large body of work for a single branded ingredient. Her own caveat is the important part: most of that research was done on eye health, and the move into cognitive health is where the science is going rather than where it already is.
She also wants the evidence extended across age groups, from pregnancy and early life through children and teenagers. That is a stated direction of travel from the company funding it, not a published result.
The GLP-1 adjacent market
The interesting commercial read here is that Kemin is not positioning Slendesta against GLP-1 drugs but alongside them. Quintela frames the opportunity as serving people who are on GLP-1, intending to start, or phasing out, and says the nutritional needs around that journey will keep shaping industry trends.
She expects 2027 to bring more maturity in the science around GLP-1 and nutrition, specifically identifying and addressing gaps. Which is a reasonable way of conceding that the gaps are currently unfilled.
Function over flora
On gut health, Quintela says there is no perfect gut and no perfect microbiome, and that Kemin believes in function over flora. The test she sets is whether an ingredient changes symptoms and quality of life rather than shifting a bacterial profile on a report.
That is a higher bar than most of this category sets for itself, and she names mechanistic evidence linked to function and symptoms as something to watch next year. She also flags gut health and women's health as a connection worth watching.
The gap nobody has closed
The hardest number in the interview is a consumption gap: Quintela puts American daily lutein intake at around 2 mg against what she says has been scientifically validated as optimal at 10 mg. After 30 years in the market, she calls that gap concerning, and suggests lutein could become the next vitamin.
No trial, publication or study name is attached to any of it, because this is a supplier outlining a roadmap at a trade show. What Kemin expects to prove by 2027 and what it has proven are different lists.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.